Literature DB >> 19331175

The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells.

Nikolaos Pissimissis1, Efstathia Papageorgiou, Peter Lembessis, Athanasios Armakolas, Michael Koutsilieris.   

Abstract

BACKGROUND: The glutamatergic system (Glu system) comprises the Glu receptors (GluRs), the Glu transporters (GluTs) and glutamine synthetase (GS).
MATERIALS AND METHODS: Using PCR-based detection and Western blot analysis, the expression of Glu system components was assessed in human androgen-independent PC-3 and androgen-dependent LNCaP prostate cancer cells.
RESULTS: iGluRs, such as NR1, NR2A, NR2C, NR2D and NR3B; mGLuRs such as mGluR1, mGluR2, mGluR3, mGluR4 and mGluR5; GluTs such as EAAT1, EAAT2, EAAT3 and EAATS; and GS mRNA were steadily expressed in both cell lines. In addition, NR3A, mGluR6, mGluR8 and EAAT4 mRNA were differentially expressed in PC-3 and LNCaP cells, mGluR7 and EAAT4 mRNA expression was induced and mGluR8 was silenced by dihydrotestosterone (DHT) treatment in LNCaP cells. GS, EAAT1 and mGLuR5 were also detected at the protein level in both PC-3 and LNCAP cells.
CONCLUSION: These data suggest that the Glu system could be an important regulator of prostate cancer cell biology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331175

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  23 in total

1.  mGlu Receptors and Cancerous Growth.

Authors:  Jessica Teh; Suzie Chen
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2011-10-25

Review 2.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population.

Authors:  Kun Wang; Jinmin Zhao; Maolin He; Mitra Fowdur; Tenglong Jiang; Shuju Luo
Journal:  Tumour Biol       Date:  2015-08-15

4.  PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Dan Li; Hong Shan; Peter Conti; Zibo Li
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

5.  mGluR6 transcripts in non-neuronal tissues.

Authors:  Tamar Vardi; Marie Fina; Lingli Zhang; Anuradha Dhingra; Noga Vardi
Journal:  J Histochem Cytochem       Date:  2011-10-27       Impact factor: 2.479

Review 6.  Metabotropic glutamate receptors in cancer.

Authors:  Lumeng J Yu; Brian A Wall; Janet Wangari-Talbot; Suzie Chen
Journal:  Neuropharmacology       Date:  2016-02-16       Impact factor: 5.250

7.  Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells.

Authors:  Shahriar Koochekpour; Sunipa Majumdar; Gissou Azabdaftari; Kristopher Attwood; Ray Scioneaux; Dhatchayini Subramani; Charles Manhardt; Giovanni D Lorusso; Stacey S Willard; Hillary Thompson; Mojgan Shourideh; Katayoon Rezaei; Oliver Sartor; James L Mohler; Robert L Vessella
Journal:  Clin Cancer Res       Date:  2012-10-16       Impact factor: 12.531

8.  The expression of Dishevelled-3 and glutamine metabolism in malignant pleural mesothelioma.

Authors:  Tong Li; Sheng-Cai Hou; Jian-Hua Mao; Yu-Cheng Wang; Xiao-Dan Lu; Jia-Li Tan; Bin You; Yu-Ping Liu; Jian Ni; Alfred Au; David M Jablons; Zhidong Xu; Liang You
Journal:  J Clin Pathol       Date:  2012-05-08       Impact factor: 3.411

9.  Host versus cell-dependent effects of β-arrestin 1 expression in prostate tumorigenesis.

Authors:  Timothy O Adekoya; Nikia Smith; Ariel J Thomas; Tonya S Lane; Nija Burnette; Elizabeth J Rivers; Yahui Li; Xiaoxin L Chen; Ricardo M Richardson
Journal:  Carcinogenesis       Date:  2021-05-28       Impact factor: 4.944

Review 10.  More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.

Authors:  Anniina Hyväkkä; Verneri Virtanen; Jukka Kemppainen; Tove J Grönroos; Heikki Minn; Maria Sundvall
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.